Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.

Published on Aug 28, 2021in The New England Journal of Medicine74.699
· DOI :10.1056/NEJMOA2108749
Marco Valgimigli (USI: University of Lugano), Dik Heg (St. Michael's Hospital)+ 28 AuthorsYoshinobu Onuma (Brighton and Sussex University Hospitals NHS Trust)
Abstract Background The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods One ...
📖 Papers frequently viewed together
14 Citations
11 Authors (Young Choi, ..., Yong-Seog Oh)
1 Citations
Cited By5
#1Yasemin Goereci (University of Cologne)H-Index: 1
#2Nina N Kleineberg (University of Cologne)H-Index: 3
Last. Henning Stetefeld (University of Cologne)H-Index: 10
view all 7 authors...
The ChAdOx1 nCoV-19 adenoviral vector vaccine to prevent contracting Covid-19 caused by infection with SARS-CoV-2 has been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily leading to venous thromboses. Here, we report two cases of major arterial occlusions after ChAdOx1 nCov-19 vaccination, comprising a 42-year-old woman with thrombotic occlusion of the left carotid artery, and a 62-year-old man with occlusion of distal aorta and iliac arteries. Both were succe...
#1Johann Auer (Paracelsus Private Medical University of Salzburg)
#2Gudrun Lamm (UHSA: University of Health Sciences Antigua)
Data from the MASTER DAPT trial indicate that the duration of dual antiplatelet therapy can be abbreviated in patients at high risk of bleeding undergoing implantation of a drug-eluting stent, resulting in a reduction in bleeding risk without an increase in ischaemic events.
#1Allan Tran (U of T: University of Toronto)
#2Theodore J. Witek (U of T: University of Toronto)H-Index: 1
The Emergency Use Authorization (EUA) originated in 2004 because of the need for emergency medical countermeasures (MCMs) against potential bioterrorist attacks. The EUA also proved useful in dealing with subsequent pandemics and has emerged as a critical regulatory pathway for therapeutics and vaccines throughout the Coronavirus Disease 2019 (COVID-19) pandemic. With the EUA process in the USA, we witnessed emergency authorizations, their expansions, as well as withdrawal of previously authoriz...